Robert Latek

9.4k total citations · 4 hit papers
31 papers, 7.6k citations indexed

About

Robert Latek is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Robert Latek has authored 31 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 10 papers in Genetics. Recurrent topics in Robert Latek's work include Cancer Immunotherapy and Biomarkers (11 papers), Glioma Diagnosis and Treatment (7 papers) and Brain Metastases and Treatment (4 papers). Robert Latek is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Glioma Diagnosis and Treatment (7 papers) and Brain Metastases and Treatment (4 papers). Robert Latek collaborates with scholars based in United States, Germany and United Kingdom. Robert Latek's co-authors include Paul Tempst, David M. Sabatini, Dos D. Sarbassov, Do‐Hyung Kim, Siraj M. Ali, Hediye Erdjument‐Bromage, Jessie E. King, David A. Guertin, George Q. Daley and Mohammad Azam and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Robert Latek

29 papers receiving 7.5k citations

Hit Papers

mTOR Interacts with Raptor to Form a Nutrient-Sensitive C... 2002 2026 2010 2018 2002 2004 2003 2017 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
    2002 2.4k citations Do‐Hyung Kim, Dos D. Sarbassov et al. Cell profile →
  2. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
    2004 2.1k citations Dos D. Sarbassov, Siraj M. Ali et al. Current Biology profile →
  3. GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR
    2003 772 citations Do‐Hyung Kim, Dos D. Sarbassov et al. Molecular Cell profile →
  4. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    2017 362 citations Antonio Omuro, Gordana Vlahovic et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Latek United States 17 5.4k 1.2k 936 889 812 31 7.6k
Roberto D. Polakiewicz United States 41 6.7k 1.2× 948 0.8× 1.4k 1.5× 606 0.7× 741 0.9× 69 9.1k
Christian Rommel United States 44 7.3k 1.3× 2.1k 1.8× 1.7k 1.8× 1.3k 1.5× 1.0k 1.3× 88 10.2k
Ivan Topisirović Canada 52 7.7k 1.4× 1.0k 0.9× 960 1.0× 410 0.5× 675 0.8× 111 9.6k
Zuzana Tóthová United States 23 6.5k 1.2× 850 0.7× 929 1.0× 554 0.6× 372 0.5× 47 8.4k
Estela Jacinto United States 27 6.9k 1.3× 1.5k 1.2× 906 1.0× 399 0.4× 965 1.2× 45 8.9k
Peter M. Finan United Kingdom 26 5.2k 1.0× 1.4k 1.2× 1.2k 1.2× 475 0.5× 954 1.2× 40 7.6k
Paolo Salomoni United Kingdom 45 4.8k 0.9× 852 0.7× 1.4k 1.5× 483 0.5× 377 0.5× 104 6.5k
Noboru Motoyama Japan 36 5.1k 1.0× 1.8k 1.5× 1.8k 1.9× 402 0.5× 746 0.9× 63 7.6k
Tomohiko Maehama Japan 32 6.2k 1.2× 937 0.8× 1.1k 1.2× 559 0.6× 1.5k 1.8× 66 7.6k
Diane C. Fingar United States 33 6.2k 1.2× 981 0.8× 932 1.0× 298 0.3× 949 1.2× 49 8.7k

Countries citing papers authored by Robert Latek

Since Specialization
Citations

This map shows the geographic impact of Robert Latek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Latek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Latek more than expected).

Fields of papers citing papers by Robert Latek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Latek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Latek. The network helps show where Robert Latek may publish in the future.

Co-authorship network of co-authors of Robert Latek

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Latek. A scholar is included among the top collaborators of Robert Latek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Latek. Robert Latek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Calvo, Emiliano, Elena Garralda, Guzmán Alonso, et al.. (2023). 1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors. Annals of Oncology. 34. S626–S626. 7 indexed citations
3.
4.
Omuro, Antonio, Gordana Vlahovic, Joachim M. Baehring, et al.. (2016). ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143. Neuro-Oncology. 18(suppl_6). vi21–vi21. 7 indexed citations
5.
6.
Lowther, Daniel E., Kent J. Weinhold, Elizabeth A. Reap, et al.. (2015). CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143. Neuro-Oncology. 17(suppl 5). v70.2–v70.
7.
Vitalone, Matthew J., Bishu Ganguly, S. Jean Hsieh, et al.. (2014). Transcriptional Profiling of Belatacept and Calcineurin Inhibitor Therapy in Renal Allograft Recipients. American Journal of Transplantation. 14(8). 1912–1921. 16 indexed citations
8.
Latek, Robert, Catherine Fleener, Edward J. Kulbokas, et al.. (2009). Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation. Transplantation. 87(6). 926–933. 81 indexed citations
9.
Boyer, Laurie A., Robert Latek, & Craig L. Peterson. (2004). The SANT domain: a unique histone-tail-binding module?. Nature Reviews Molecular Cell Biology. 5(2). 158–163. 305 indexed citations
10.
Sarbassov, Dos D., Siraj M. Ali, Do‐Hyung Kim, et al.. (2004). Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton. Current Biology. 14(14). 1296–1302. 2141 indexed citations breakdown →
11.
Yuan, Bo, Robert Latek, Markus Hoßbach, Thomas Tuschl, & F. Lewitter. (2004). siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Research. 32(Web Server). W130–W134. 255 indexed citations
12.
Xiao, Zhan, Robert Latek, & Harvey F. Lodish. (2003). An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity. Oncogene. 22(7). 1057–1069. 88 indexed citations
13.
Nagahara, Hikaru, Robert Latek, Sergei A. Ezhevsky, & Steven F. Dowdy. (2003). 2-D Phosphopeptide Mapping. Humana Press eBooks. 112. 271–280. 6 indexed citations
14.
Azam, Mohammad, Robert Latek, & George Q. Daley. (2003). Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell. 112(6). 831–843. 492 indexed citations
15.
Kim, Do‐Hyung, Dos D. Sarbassov, Siraj M. Ali, et al.. (2003). GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR. Molecular Cell. 11(4). 895–904. 772 indexed citations breakdown →
16.
Tootle, Tina L., Serena J. Silver, Erin L. Davies, et al.. (2003). The transcription factor Eyes absent is a protein tyrosine phosphatase. Nature. 426(6964). 299–302. 205 indexed citations
17.
Kim, Do‐Hyung, Dos D. Sarbassov, Siraj M. Ali, et al.. (2002). mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery. Cell. 110(2). 163–175. 2398 indexed citations breakdown →
18.
Latek, Robert, Anish Suri, Shirley J. Petzold, et al.. (2000). Structural Basis of Peptide Binding and Presentation by the Type I Diabetes-Associated MHC Class II Molecule of NOD Mice. Immunity. 12(6). 699–710. 166 indexed citations
19.
Latek, Robert & Emil R. Unanue. (1999). Mechanisms and consequences of peptide selection by the I‐Ak class II molecule. Immunological Reviews. 172(1). 209–228. 36 indexed citations
20.
Leidich, Steven D., Zlatka Kostova, Robert Latek, et al.. (1995). Temperature-sensitive Yeast GPI Anchoring Mutants gpi2 and gpi3 Are Defective in the Synthesis of N-Acetylglucosaminyl Phosphatidylinositol.. Journal of Biological Chemistry. 270(22). 13029–13035. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberto D. Polakiewicz Breakdown of academic impact, for papers by Christian Rommel Breakdown of academic impact, for papers by Ivan Topisirović Breakdown of academic impact, for papers by Zuzana Tóthová Breakdown of academic impact, for papers by Estela Jacinto Breakdown of academic impact, for papers by Peter M. Finan Breakdown of academic impact, for papers by Paolo Salomoni Breakdown of academic impact, for papers by Noboru Motoyama Breakdown of academic impact, for papers by Tomohiko Maehama Breakdown of academic impact, for papers by Diane C. Fingar
Rankless by CCL
2026